Arcutis Biotherapeutics reports positive Phase 3 STRATUM results for roflumilast foam in seborrheic dermatitis

Arcutis Biotherapeutics, Inc.

80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)
50.7% achieved an IGA score of clear at week 8 compared to 28.2% with vehicle (p<0.0001)
Treatment was well-tolerated; discontinuation due to adverse events was 0.7% for roflumilast vs 2.0% for vehicle
NDA submission to FDA for roflumilast foam in seborrheic dermatitis anticipated in first half of 2023

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.